← Back to Search

Influenza Vaccine

Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1 for Flu

Phase 2
Waitlist Available
Research Sponsored by Seqirus
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 days post-vaccination
Awards & highlights

Study Summary

This trial is studying different ways to give the flu vaccine to people. They want to see if it is better to give it one way or another. They will follow up with the people who got the vaccine to see how well it worked.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 days post-vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 days post-vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Immunogenicity Endpoint: Hemagglutination inhibition (HI) titers against vaccine A and B influenza strains
The Percentage of Subjects with Serious Adverse Events (SAEs), AEs Leading to Withdrawal, Adverse Events of Special Interest (AESI) and Medically Attended Adverse Events (MAAEs)
The Percentage of Subjects with Solicited Local and Systemic Reactions
+1 more
Secondary outcome measures
Immunogenicity Endpoint: Microneutralization (MN) titers against vaccine A and B influenza strains

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: aIIV-C InvestigationalExperimental Treatment1 Intervention
Group II: aIIV-B InvestigationalExperimental Treatment1 Intervention
Group III: IIV-A InvestigationalExperimental Treatment1 Intervention
Group IV: Licensed IIVActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1
2022
Completed Phase 2
~1060
Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1
2022
Completed Phase 2
~1060
Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1
2022
Completed Phase 2
~1060

Find a Location

Who is running the clinical trial?

SeqirusLead Sponsor
59 Previous Clinical Trials
1,080,014 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there anycurrent vacancies for this research program?

"This particular clinical trial, which was first posted on August 25th, 2022, is not currently seeking patients for participation. Although, there are 123 other trials that are still open for enrolment."

Answered by AI

Is the FDA aware of the potential benefits of aIIV-B?

"Because this is a Phase 2 trial, Power's team has estimated that the safety of Experimental: aIIV-B will be a 2. This is due to some data supporting safety, but no data supporting efficacy."

Answered by AI

Is this clinical trial being conducted at more than one hospital in the city?

"Patients are currently being accepted at 4 different locations: California Research Center in San Diego, California, JBR Clinical Research in Salt Lake City, Utah, The Lynn Institute of The Rockies in Colorado Springs, Colorado, and 46 other sites."

Answered by AI

Who else is applying?

What state do they live in?
District of Columbia
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age
2022. "Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05501561.
~409 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top